All Drug Delivery articles – Page 3
-
NewsVirus-mimicking LENN nanoparticles deliver mRNA to bladder cancer cells
Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.
-
NewsBeige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
-
NewsNew fluorescent technology tracks drug responses in cells
Researchers have developed new innovative fluorescent labels that allow scientists to observe cellular processes with unprecedented clarity – offering a powerful tool for medicine, drug research and cell biology.
-
NewsNew AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
-
NewsTRPM5 protein switch discovery could lead to new diabetes drugs
Northwestern University scientists have discovered a hidden ‘control switch’ in the TRPM5 protein, which helps regulate taste, blood sugar and gut health and could lead to new therapies for targeting diabetes and obesity.
-
NewsPolysaccharide microneedles: the future of cancer immunotherapy
Polysaccharide-based microneedles are emerging as a dual-action platform for cancer immunotherapy, delivering anti-cancer drugs directly to the skin while actively modulating the immune system.
-
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
-
ArticleWhy patient-derived biology matters for ADC discovery
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
-
NewsUltra-stable hydrogel boosts gastrointestinal wound repair
PolyU researchers have developed a new acid-resistant hydrogel inspired by natural gastric mucus that adheres far better than current treatments.
-
ArticleBuilding better biologics and a stronger future for women in STEM
Great biologics don’t happen by chance, and neither do great STEM careers. Dr Lidia Serina shares the lessons behind both.
-
NewsInhibiting DDR1 pathway helps breach pancreatic cancer’s drug barrier
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
-
ArticleRNA that lasts longer and lands exactly where it should
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
-
NewsPlatelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness.
-
ArticleRNA that knows where to go: the rise of targeted delivery
What if RNA medicines could be guided directly to tumours, sparing healthy tissue and reducing side effects? Advances in targeted delivery are bringing that vision closer to reality.
-
NewsBits2Bonds: AI system accelerates discovery of RNA delivery polymers
Researchers at LMU Munich have developed Bits2Bonds, the first platform to fuse molecular simulations with machine learning – accelerating the discovery of polymer carriers for therapeutic RNA.
-
ArticleRedesigning paclitaxel: expanding the therapeutic window through oral delivery
The potent chemotherapy drug paclitaxel is widely employed for various cancers despite toxicity and efficacy challenges. Maite Agüeros reveals how novel nanoparticle technology has enabled oral delivery of the drug – showing promising signs of improved tolerability and treatment success.
-
NewsNew mRNA therapy targets drug-resistant pneumonia
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
-
NewsSamsung invests in Phrontline to advance next-gen ADC therapies
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
-
ArticleFast, scalable free energy prediction with nonequilibrium switching
Nonequilibrium switching (NES) offers a faster, more scalable way to predict how strongly drugs bind to their targets. By replacing slow equilibrium simulations with rapid, parallel transitions, NES delivers accurate free energy predictions at speed.
-
NewsOral arginine reduces harmful amyloid in Alzheimer’s models
A naturally occurring amino acid commonly found in supplements has reduced harmful amyloid build-up and eased symptoms in animal models of Alzheimer’s disease.